Journal
BIODRUGS
Volume 22, Issue 4, Pages 209-222Publisher
ADIS INT LTD
DOI: 10.2165/00063030-200822040-00001
Keywords
-
Categories
Funding
- NHLBI NIH HHS [T32 HL07843, R01 HL089315, F32 HL 79769, K08 HL072812] Funding Source: Medline
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL072812, F32HL079769, R01HL089315, T32HL007843] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Coronary artery and peripheral vascular disease are global health concerns with limited therapies. Currently available medical and surgical therapies for these disease processes are highly effective for only a fraction of patients. Extensive effort has been devoted to finding molecular therapies to enhance perfusion and function of ischemic myocardial and peripheral skeletal muscle. Angiogenic cytokines (fibroblast growth factor [FGF], vascular endothelial growth factor [VEGF], hepatocyte growth factor [HGF], placental growth factor, stromal cell-derived factor-1 alpha) have shown theoretical and experimental promise in upregulating endogenous endothelial progenitor cell-mediated angiogenesis. Preliminary clinical trials have suggested improvements in myocardial and peripheral perfusion following therapy with FGF, VEGF, and HGF. Further studies on the efficacy of cytokine-mediated angiogenesis are required before widespread clinical application is possible. Investigation into adjunctive cytokine therapies for myocardial and peripheral muscle ischemia is warranted. Based on experimental evidence, appropriate angiogenic cytokine therapy should provide benefits in both perfusion and hemodynamic function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available